Jessica Sage Little, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycobacterium chelonae | 1 | 2022 | 12 | 0.820 |
Why?
|
Bacteriophages | 2 | 2023 | 372 | 0.800 |
Why?
|
Agammaglobulinemia | 1 | 2023 | 173 | 0.790 |
Why?
|
Skin Diseases, Bacterial | 1 | 2022 | 68 | 0.770 |
Why?
|
Opportunistic Infections | 1 | 2023 | 375 | 0.730 |
Why?
|
Cytomegalovirus Infections | 2 | 2023 | 831 | 0.700 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2024 | 5648 | 0.580 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 608 | 0.570 |
Why?
|
Respiratory Tract Infections | 1 | 2023 | 1004 | 0.510 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1373 | 0.490 |
Why?
|
Graft vs Host Disease | 2 | 2024 | 3024 | 0.390 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2685 | 0.370 |
Why?
|
Health Personnel | 1 | 2020 | 3309 | 0.280 |
Why?
|
B-Cell Maturation Antigen | 2 | 2023 | 148 | 0.250 |
Why?
|
Parvovirus B19, Human | 1 | 2024 | 40 | 0.230 |
Why?
|
Herpesvirus 6, Human | 1 | 2024 | 96 | 0.220 |
Why?
|
Immunotherapy, Adoptive | 2 | 2023 | 1454 | 0.210 |
Why?
|
Physicians | 1 | 2020 | 4577 | 0.200 |
Why?
|
Herpesvirus 8, Human | 1 | 2024 | 255 | 0.200 |
Why?
|
Antigens, CD34 | 1 | 2024 | 653 | 0.200 |
Why?
|
Clarithromycin | 1 | 2022 | 85 | 0.200 |
Why?
|
Mycobacterium | 1 | 2023 | 251 | 0.190 |
Why?
|
Antigens, CD19 | 1 | 2022 | 423 | 0.170 |
Why?
|
Cell Count | 1 | 2022 | 1834 | 0.150 |
Why?
|
Treatment Failure | 1 | 2024 | 2637 | 0.150 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1075 | 0.150 |
Why?
|
Cyclophosphamide | 1 | 2023 | 2219 | 0.150 |
Why?
|
Antifungal Agents | 1 | 2022 | 749 | 0.140 |
Why?
|
Patient Care Management | 1 | 2020 | 302 | 0.140 |
Why?
|
Cystic Fibrosis | 1 | 2023 | 1274 | 0.110 |
Why?
|
Tissue Donors | 1 | 2022 | 2311 | 0.100 |
Why?
|
Retrospective Studies | 5 | 2024 | 79984 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1890 | 0.100 |
Why?
|
Evoked Potentials, Visual | 1 | 2012 | 415 | 0.090 |
Why?
|
Patient Positioning | 1 | 2012 | 326 | 0.090 |
Why?
|
Adult | 5 | 2024 | 219725 | 0.080 |
Why?
|
Posture | 1 | 2012 | 954 | 0.080 |
Why?
|
Humans | 12 | 2024 | 757566 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7399 | 0.070 |
Why?
|
Transplantation, Homologous | 2 | 2024 | 4808 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9245 | 0.060 |
Why?
|
Visual Cortex | 1 | 2012 | 1089 | 0.060 |
Why?
|
Parvoviridae Infections | 1 | 2024 | 36 | 0.060 |
Why?
|
Models, Neurological | 1 | 2012 | 1757 | 0.060 |
Why?
|
Incidence | 1 | 2022 | 21217 | 0.060 |
Why?
|
Roseolovirus Infections | 1 | 2024 | 49 | 0.060 |
Why?
|
Compassionate Use Trials | 1 | 2023 | 50 | 0.050 |
Why?
|
Herpesviridae Infections | 1 | 2024 | 270 | 0.050 |
Why?
|
Brain Mapping | 1 | 2012 | 6571 | 0.040 |
Why?
|
Electroencephalography | 1 | 2012 | 6187 | 0.030 |
Why?
|
Risk Factors | 1 | 2022 | 73708 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 1087 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2024 | 3055 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3146 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4540 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 58755 | 0.010 |
Why?
|
Aged | 2 | 2024 | 167890 | 0.010 |
Why?
|
Middle Aged | 2 | 2024 | 219192 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6198 | 0.010 |
Why?
|
Male | 3 | 2024 | 358180 | 0.010 |
Why?
|
Adolescent | 1 | 2024 | 87819 | 0.010 |
Why?
|
Female | 2 | 2024 | 389943 | 0.010 |
Why?
|